11 November 2013
ByAppeared in BioNews 730
'The creation of Spark is the culmination of a decade-long commitment by CHOP and our founding team to drive the field of gene therapy forward during a time when many in the industry had moved away,' said Jeffrey Marrazzo, CEO of Spark Therapeutics.
This stage builds on earlier work that saw 12 patients with RPE65-related retinal degeneration demonstrate 'notable improvement in visual function', as reported by Spark Therapeutics. The company is also conducting early-stage clinical trials for haemophilia and studies to address neurodegenerative conditions, blood disorders and other forms of inherited blindness.
CHOP has taken a more hands-on approach in this venture with most of Spark Therapeutics' management and advisers coming from its Center for Cellular and Molecular Therapeutics.
'It's a bold move', Gary Kurtzman, managing director for healthcare at Safeguard Scientifics told The Philadelphia Inquirer. 'Based on the technology and the assets and the expertise, I think it's a very smart move'.